PD-L1 Binding Molecules and Uses Thereof

USPTO issued Patent US12590155B2 to Beijing Mabworks Biotech Co., Ltd. covering PD-L1 binding molecules including single-domain antibodies and heavy chain only antibodies. The patent, invented by Xuechen Zhou, Guangzhong Lin, Jiangmei Li, Wenqi Hu, and Feng Li, claims molecules that specifically bind human PD-L1 and their use in treating diseases, particularly tumors (A61P 35/00). Filing date was May 25, 2023, with Application No. 18323645.

Patent holders and licensees should verify freedom-to-operate for PD-L1 targeting therapeutics. Competitors developing similar PD-L1 binding molecules should assess potential infringement risks. The patent provides the assignee with exclusive rights to the claimed molecules and methods in the United States for the patent term.